MKC 1106-MT

Drug Profile

MKC 1106-MT

Alternative Names: MKC 1207; MKC1106-MT; pSEM; Synchrovax™ SEM

Latest Information Update: 11 Feb 2016

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator CTL ImmunoTherapies Corporation
  • Developer Colby Pharmaceuticals; MannKind Corporation
  • Class Cancer vaccines; DNA vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • No development reported Malignant melanoma

Most Recent Events

  • 10 Feb 2016 No development reported - Phase-II for Malignant melanoma in USA (Intralymphatic)
  • 13 Nov 2012 MKC 1106-MT licensed to Colby Pharmaceutical Company worldwide
  • 20 Oct 2010 Phase-II clinical trials in Malignant melanoma in USA (Intralymphatic)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top